<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Lindhardt | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/inputflame4/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/inputflame4/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Lindhardt.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">b445e04b9fddf3e8d2226f7dd0d871ae</guid>
				<title>Lindhardt posted an update: 7.3% -38.7% ) , 20.6% (95% CI 20.0% -21.3% ) ], disease-free [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41859/</link>
				<pubDate>Sat, 08 Feb 2025 11:20:50 -0800</pubDate>

									<content:encoded><![CDATA[<p>7.3% -38.7% ) , 20.6% (95% CI 20.0% -21.3% ) ], disease-free survival [53.3% (95% CI 44.9% -63.4% ) , 51.9% (95% CI 41% -65.8% ) , 63.9% (95% CI 51.9% -78.7% ) ] and non-relapse mortality [24.2% (95% CI 23.8% -24.5% ) , 26.0% (95% CI 25.4% -26.6% ) , 23.6% (95% CI 26.3% -28.2% ) ] (P=0.648, P=0.165, and P=0.486 and P=0.955) . Conclusion Low dose&hellip;<span class="activity-read-more" id="activity-read-more-41859"><a href="http://www.nationalboardinstitute.com/activity/p/41859/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f1f3427cb89c26a8b1336ad5e3f0e2e7</guid>
				<title>Lindhardt posted an update: While further studies are needed, these results show careful [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/39324/</link>
				<pubDate>Wed, 05 Feb 2025 12:34:41 -0800</pubDate>

									<content:encoded><![CDATA[<p>While further studies are needed, these results show careful CPA loading and higher metal forms warming rates can help reduce CPA loading toxicity and improve outcomes from cryopreservation in tissues while also offering new protocols to preserve larger tissues ≥1 mm in thickness.The present pandemic has hurled organizations into a new social &#8220;&hellip;<span class="activity-read-more" id="activity-read-more-39324"><a href="http://www.nationalboardinstitute.com/activity/p/39324/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">9eef2409e782b43891f16ca7ff028d5c</guid>
				<title>Lindhardt posted an update: A 19-year-old man presented with acute severe ulcerative [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/37707/</link>
				<pubDate>Mon, 03 Feb 2025 11:54:48 -0800</pubDate>

									<content:encoded><![CDATA[<p>A 19-year-old man presented with acute severe ulcerative colitis. He was taking azathioprine (therapeutic metabolites) and sulphasalazine as well as infliximab with a therapeutic drug level. <a href="https://www.selleckchem.com/products/dt-2216.html" rel="nofollow ugc">DT2216 clinical trial</a> On day 3 of hydrocortisone therapy, he met day Oxford criteria with &gt;8 bloody stools per day and was given faecal microbiota&hellip;<span class="activity-read-more" id="activity-read-more-37707"><a href="http://www.nationalboardinstitute.com/activity/p/37707/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f2e30417cb2e835f977bf8236765cb49</guid>
				<title>Lindhardt posted an update: New data is emerging to guide initial treatment of patients [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/35934/</link>
				<pubDate>Sat, 01 Feb 2025 11:55:40 -0800</pubDate>

									<content:encoded><![CDATA[<p>New data is emerging to guide initial treatment of patients with metastatic prostate cancer (CaP). This study utilizes the Cancer of the Prostate Strategic Urologic Research Endeavor registry to evaluate variations in survival based on initial treatment received by men with metastatic disease at diagnosis or after progression.</p>
<p> Cancer of&hellip;<span class="activity-read-more" id="activity-read-more-35934"><a href="http://www.nationalboardinstitute.com/activity/p/35934/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">35931dc93931dc6cadadcb4fe4c1bff6</guid>
				<title>Lindhardt posted an update: thus be effective for veterans irrespective of MST [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/34991/</link>
				<pubDate>Fri, 31 Jan 2025 12:28:30 -0800</pubDate>

									<content:encoded><![CDATA[<p>thus be effective for veterans irrespective of MST history.High levels of aldosterone appear to be related to depressive and anxiety related behavior as demonstrated in therapy refractory depression and primary aldosteronism (PA). We analyzed data from a large register of patients with PA in order to clarify mediators and moderators of this&hellip;<span class="activity-read-more" id="activity-read-more-34991"><a href="http://www.nationalboardinstitute.com/activity/p/34991/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">4d05fbf9325fc6186514e8ec7cda4c0c</guid>
				<title>Lindhardt became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/32093/</link>
				<pubDate>Tue, 28 Jan 2025 17:53:43 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>